We report a novel missense mutation p.T145K in the insulin-like growth factor (IGF) acid-labile subunit (IGFALS) gene identified in a Turkish patient with normal growth, transient pancytopenic episodes and signs of immunological dysfunction. Because of recurrent cutaneous mycoses and absence of pubertal development until the age of 14.75 years we determined several endocrine parameters in order to rule out autoimmune-polyendocrine syndromes. Despite a normal height between the 25th and 50th percentile we found severely decreased IGF-1 and undetectably low IGFBP-3 levels. Laboratory signs of immunological dysfunction included reduced total lymphocyte count with diminished B and T helper cell fractions, decreased serum concentrations of IgM and IgG subclass 4, and elevated antinuclear antibody and anti-dsDNA titers as well as persistently high interleukin-2-receptor levels. Further endocrine work-up revealed elevated fasting insulin and undetectably low ALS serum levels, leading to the diagnosis of ALS deficiency. Sequencing of the coding region of the IGFALS gene showed a novel homozygous missense mutation (c.434C>A; p.T145K). Since immunological abnormalities have not been reported in more than 20 ALS-deficient patients so far and our patient was born to consanguineous parents, a second autosomal recessive defect is likely to underlie the immunological phenotype, although a causative role of IGFALS p.T145K cannot be entirely ruled out.

1.
Guler HP, Zapf J, Schmid C, Froesch ER: Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol (Copenh) 1989;121:753-758.
2.
Domené HM, Bengolea SV, Martínez AS, Ropelato MG, Pennisi P, Scaglia P, Heinrich JJ, Jasper HG: Deficiency of the circulating insulin-like growth factor system associated with inactivation of the acid-labile subunit gene. N Engl J Med 2004;350:570-577.
3.
Domené HM, Hwa V, Jasper HG, Rosenfeld RG: Acid-labile subunit (ALS) deficiency. Best Pract Res Clin Endocrinol Metab 2011;25:101-113.
4.
Hess O, Khayat M, Hwa V, Heath KE, Teitler A, Hritan Y, Allon-Shalev S, Tenenbaum-Rakover Y: A novel mutation in IGFALS, c.380T>C (p.L127P), associated with short stature, delayed puberty, osteopenia and hyperinsulinaemia in two siblings: insights into the roles of insulin growth factor-1 (IGF1). Clin Endocrinol (Oxf), E-pub ahead of print.
5.
Domené HM, Hwa V, Argente J, Wit JM, Camacho-Hübner C, Jasper HG, Pozo J, van Duyvenvoorde HA, Yakar S, Fofanova-Gambetti OV, Rosenfeld RG, International ALS Collaborative Group: Human acid-labile subunit deficiency: clinical, endocrine and metabolic consequences. Horm Res 2009;72:129-141.
6.
Redlefsen T, Commentz J, Meigen C, Hermanussen M: Reference values for height, weight and body mass index of German born Turkish children. Anthropol Anz 2007;65:263-274.
7.
Redlefsen T: Perzentilenkurven für in Deutschland geborene Kinder türkischer Abstammung für Körperlänge, Körpergewicht und BMI. http://ediss.sub.uni-hamburg.de/volltexte/2008/3745/.
8.
Özer BK: Secular trend in body height and weight of Turkish adults. Anthropol Sci 2008;116:191-199.
9.
Kurtoğlu S, Hatipoğlu N, Mazıcıoğlu MM, Akın MA, Çoban D, Gökoğlu S, Baştuğ O: Body weight, length and head circumference at birth in a cohort of Turkish newborns. J Clin Res Pediatr Endocrinol 2012;4:132-139.
10.
Juul A, Moller S, Mosfeldt-Laursen E, Rasmussen MH, Scheike T, Pedersen SA, Kastrup KW, Yu H, Mistry J, Rasmussen S, Müller J, Henriksen J, Skakkebaek NE: The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulating concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency. J Clin Endocrinol Metab 1998;83:4408-4415.
11.
Van Duyvenvoorde HA, Kempers MJ, Twickler TB, van Doorn J, Gerver WJ, Noordam C, Losekoot M, Karperien M, Wit JM, Hermus AR: Homozygous and heterozygous expression of a novel mutation of the acid-labile subunit. Eur J Endocrinol 2008;159:113-120.
12.
Hwa V, Haeusler G, Pratt KL, Little BM, Frisch H, Koller D, Rosenfeld RG: Total absence of functional acid labile subunit, resulting in severe insulin-like growth factor deficiency and moderate growth failure. J Clin Endocrinol Metab 2006;91:1826-1831.
13.
Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, Pintar JE: Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol 2006;20:2173-2186.
14.
Fofanova-Gambetti OV, Hwa V, Wit JM, Domene HM, Argente J, Bang P, Högler W, Kirsch S, Pihoker C, Chiu HK, Cohen L, Jacobsen C, Jasper HG, Haeusler G, Campos-Barros A, Gallego-Gómez E, Gracia-Bouthelier R, van Duyvenvoorde HA, Pozo J, Rosenfeld RG: Impact of heterozygosity for acid-labile subunit (IGFALS) gene mutation on stature: results from the International Acid Labile Subunit Consortium. J Clin Endocrinol Metab 2010;95:4184-4191.
15.
Jogie-Brahim S, Feldman D, Oh Y: Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev 2009;30:417-437.
16.
Wang L, Habuchi T, Tsuchiya N, Mitsumori K, Ohyama C, Sato K, Kinoshita H, Kamoto T, Nakamura A, Ogawa O, Kato T: Insulin-like growth factor-binding protein-3 gene -202 A/C polymorphism is correlated with advanced disease status in prostate cancer. Cancer Res 2003;63:4407-4411.
17.
Hankinson SE, Willett WC, Colditz GA, Hunter DJ, Michaud DS, Deroo B, Rosner B, Speizer FE, Pollak M: Circulating concentrations of insulin-like growth factor-I and risk of breast cancer. Lancet 1998;351:1393-1396.
18.
Ma J, Pollak MN, Giovannucci E, Chan JM, Tao Y, Hennekens CH, Stampfer MJ: Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor(IGF)-1 and IGF-binding protein-3. J Natl Cancer Inst 1999;91:620-625.
19.
Yu H, Spitz MR, Mistry J, Gu J, Hong WK, Wu X: Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis. J Natl Cancer Inst 1999;91:151-156.
20.
Fanayan S, Firth SM, Butt AJ, Baxter RC: Growth inhibition by insulin-like growth factor binding protein-3 in T47D breast cancer cells requires transforming growth factor-β (TGF-β) and the type II TGF-β receptor. J Biol Chem 2000;275:39146-39151.
21.
Rajah R, Lee KW, Cohen P: Insulin-like growth factor binding protein-3 mediates tumor necrosis factor-α-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 2002;13:163-171.
22.
Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P: Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRα/Nur77. J Biol Chem 2005;280:16942-16948.
23.
Ingermann AR, Yang YF, Han J, Mikami A, Garza AE, Mohanraj L, Fan L, Idowu M, Ware JL, Kim HS, Lee DY, Oh Y: Identification of a novel cell death receptor mediating IGFBP-3-induced anti-tumor effects in breast and prostate cancer. J Biol Chem 2010;285:30233-30246.
24.
Lee YC, Jogie-Brahim S, Lee DY, Han J, Harada A, Murphy LJ, Oh Y: Insulin-like growth factor-binding protein-3 (IGFBP-3) blocks the effects of asthma by negatively regulating NF-κB signaling through IGFBP-3R-mediated activation of caspases. J Biol Chem 2011;286:17898-17909.
25.
Hwa V, Nadeau K, Wit JM, Rosenfeld RG: STAT5b deficiency: lessons from STAT5b gene mutations. Best Pract Res Clin Endocrinol Metab 2011;25:61-75.
26.
Kimura A, Rieger MA, Simone JM, Chen W, Wickre MC, Zhu BM, Hoppe PS, O'Shea JJ, Schroeder T, Hennighausen L: The transcription factors STAT5A/B regulate GM-CSF-mediated granulopoiesis. Blood 2009;114:4721-4728.
27.
Bell BD, Kitajima M, Larson RP, Stoklasek TA, Dang K, Sakamoto K, Wagner KU, Reizis B, Hennighausen L, Ziegler SF: The transcription factor STAT5 is critical in dendritic cells for the development of TH2 but not TH1 responses. Nat Immunol 2013;14:364-371.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.